Clinical trials: Progressive Supranuclear Palsy
Progressive Supranuclear Palsy
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT02605785
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Progressive Supranuclear Palsy
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP).
- Trial name
- NCT05819658
- Testing
- GV1001 0.56mg, GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GemVax & Kael
Progressive Supranuclear Palsy, Healthy Volunteers
Evaluation of [18F]APN-1607 as a PET Biomarker
The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
- Trial name
- NCT05005819
- Testing
- [18F] APN-1607
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Essential Tremor, Multiple System Atrophy
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.
- Conditions
- Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive
- Trial name
- PHENO (NCT02132052)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Colorado, Denver
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
Vaccination Uptake (VAX) in PD
This is a study to see whether participation in the Edmond J. Safra Interdisciplinary Home Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate vaccinations in people with advanced Parkinson's…
- Trial name
- VAX-PD (NCT02874274)
- Testing
- Standard of Care, Home Visit Program (HVP)
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- NYU Langone Health
Parkinson Disease, Multiple System Atrophy
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
The purpose of this study is to determine the efficacy of Droxidopa for the treatment of fatigue in patients with Parkinsonism by the Visual Analog Fatigue Scale (VAFS).
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT03446807
- Testing
- Droxidopa
- Where
- United States
- Sponsor
- Loma Linda University
Vascular Parkinsonism, Drug-induced Parkinsonism
AI-Enhanced Optimization of Acute Levodopa Challenge Test
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence.
- Conditions
- Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
- Trial name
- NCT06949865
- Testing
- video recording
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
PSP - Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- NCT07264283
- Testing
- LM11A-31
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Adam Boxer
Progressive Supranuclear Palsy, Multiple System Atrophy
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design.
- Trial name
- EMERA006 (NCT04184063)
- Testing
- NBMI
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- EmeraMed
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Progressive Supranuclear Palsy
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
- Trial name
- NCT02494024
- Testing
- Single dose C2N-8E12
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- C2N Diagnostics
Alzheimer Disease, Progressive Supranuclear Palsy
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD).
- Conditions
- Alzheimer Disease, Progressive Supranuclear Palsy, Frontotemporal Dementia
- Trial name
- NCT05260151
- Where
- China
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Parkinson Disease, Progressive Supranuclear Palsy(PSP)
Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
This is an observational longitudinal study in 4 cohorts of patients with Parkinsonian syndromes, who are visiting the Movement Disorders outpatient clinics.
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy
- Trial name
- PARATROOPER (NCT06597071)
- Testing
- NeuraLight PD, NeuraLight PSP, NeuraLight MSA
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuraLight
Parkinson Disease, Multiple System Atrophy, Parkinson Variant
Automated Imaging Differentiation of Parkinsonism
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
- Trial name
- AIDP (NCT05913687)
- Testing
- AIDP
- Where
- 21 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of Florida
Predicted Tauopathies, Including, Progressive Supranuclear Palsy
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology…
- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome
- Trial name
- NCT01056965
- Testing
- davunetide (AL-108, NAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Progressive Supranuclear Palsy
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
This is a randomized, placebo-controlled trial of RT001 in patients with PSP.
- Trial name
- NCT04937530
- Testing
- RT001
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Biojiva LLC
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Progressive Supranuclear Palsy, Corticobasal Degeneration
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge.
- Trial name
- APOPARKA (NCT04786158)
- Testing
- Apomorphine
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild